Seqens Seqens

X
[{"orgOrder":0,"company":"TOA EIYO","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas and TOA EIYO Announce Termination of Distribution Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by TOA EIYO

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            In accordance with this agreement TOA EIYO will independently sell and provide information on all 18 products such as Bisono® tape for treatment of hypertension and atrial fibrillation and Frandol® tablets and tape for treatment of ischemic heart disease.

            Lead Product(s): Isosorbide Dinitrate

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Frandol

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Astellas Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination April 05, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY